

1. Sex Differences in Long-Term Outcomes in Patients With Chronic Coronary Syndrome After Percutaneous Coronary Intervention - Insights From a Japanese Real-World Database Using a Storage System. Akashi N, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, Kario K, **Kiyosue A**, Mizuno Y, Nochioka K, Nakayama M, Iwai T, Miyamoto Y, Ishii M, Nakamura T, Tsujita K, Sato H, Fujita H, Nagai R; CLIDAS Research Group. *Circ J*. 2023 May 25;87(6):775-782.
2. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Akashi N, Kuwabara M, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, Kario K, **Kiyosue A**, Mizuno Y, Nochioka K, Nakayama M, Iwai T, Nakao Y, Iwanaga Y, Miyamoto Y, Ishii M, Nakamura T, Tsujita K, Sato H, Fujita H, Nagai R. *Front Cardiovasc Med*. 2023 Jan 10;9:1062894.
3. Potential value of saline-induced Pd/Pa ratio in patients with coronary artery stenosis. Kiriya H, **Kiyosue A**, Minatsuki S, Kawahara T, Katsushika S, Kamon T, Hirose K, Shinohara H, Miura M, Saito A, Kikuchi H, Kodera S, Hatano M, Ando J, Myojo M, Itoh N, Yamamoto K, Ikenouchi H, Takeda N, Komuro I. *Front Cardiovasc Med*. 2023 Jan 6;9:1001833.
4. Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia - A Post-Marketing Survey (J-POSSIBLE). **Kiyosue A**, Yasuda S, Tomura A, Usami M, Arai H. *Circ J*. 2023 May 25;87(6):834-846.
5. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). **Kiyosue A**, Dunn JP, Cui X, Hickey A, Hirase T, Imaoka T, Heine RJ. *Diabetes Obes Metab*. 2023 Apr;25(4):1056-1067.
6. Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, **Kiyosue A**, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. *N Engl J Med*. 2022 Jul 21;387(3):205-216.
7. Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial. Tanaka A, Imai T, Suzuki M, Hiramitsu S, Takahashi N, Kadokami T, **Kiyosue A**, Nishino M, Sakata Y, Node K; CANDLE trial investigators. *Diabetes Obes Metab*. 2022 May;24(5):962-965.

8. A Novel Technique of Balloon Pulmonary Angioplasty for the Treatment of Total Occlusion Lesions. Minatsuki S, [Kiyosue A](#), Shimizu Y, Tanikawa I, Murasawa T, Hirose K, Saito A, Yagi H, Takeda N, Hatano M, Ando J, Komuro I. *CJC Open*. 2021 Jul 13;3(12):1513-1515.
9. Detection of Profound Myocardial Damage by Cardiac MRI in a Patient with Severe Cardiotoxicity Induced by Anti-HER2 Therapy. Kadowaki H, Ishida J, Uehara M, Ishizuka M, [Kiyosue A](#), Hatano M, Shimada S, Ono M, Akazawa H, Komuro I. *Int Heart J*. 2021;62(6):1436-1441.
10. Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry. Minatsuki S, Takahara M, [Kiyosue A](#), Kodera S, Hatano M, Ando J, Kohsaka S, Ishii H, Shinke T, Amano T, Ikari Y, Komuro I; J-SHD and J-PCI Investigators. *Open Heart*. 2021 Sep;8(2):e001721.
11. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents. Tanaka A, Toyoda S, Imai T, Shiina K, Tomiyama H, Matsuzawa Y, Okumura T, Kanzaki Y, Onishi K, [Kiyosue A](#), Nishino M, Sakata Y, Node K; CANDLE trial investigators. *Cardiovasc Diabetol*. 2021 Sep 3;20(1):175.
12. Automatic detection of vessel structure by deep learning using intravascular ultrasound images of the coronary arteries. Shinohara H, Kodera S, Ninomiya K, Nakamoto M, Katsushika S, Saito A, Minatsuki S, Kikuchi H, [Kiyosue A](#), Higashikuni Y, Takeda N, Fujiu K, Ando J, Akazawa H, Morita H, Komuro I. *PLoS One*. 2021 Aug 5;16(8):e0255577.
13. Factors associated with left ventricular reverse remodelling after percutaneous coronary intervention in patients with left ventricular systolic dysfunction. Adachi Y, [Kiyosue A](#), Ando J, Kawahara T, Kodera S, Minatsuki S, Kikuchi H, Inaba T, Kiriya H, Hirose K, Shinohara H, Saito A, Fujiwara T, Hara H, Ueda K, Sakakura K, Hatano M, Harada M, Takimoto E, Akazawa H, Morita H, Momomura SI, Fujita H, Komuro I. *Sci Rep*. 2021 Jan 8;11(1):239.
14. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. Kario K, Nishizawa M, Kiuchi M, [Kiyosue A](#), Tomita F, Ohtani H, Abe Y, Kuga H, Miyazaki S, Kasai T, Hongou M, Yasu T, Kuramochi J, Fukumoto Y, Hoshida S, Hisatome I. *J Clin Hypertens (Greenwich)*. 2021 Feb;23(2):334-344.
15. Efficacy of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Patients with Angina Pectoris. Shinohara H, Kodera S, [Kiyosue A](#), Ando J, Morita H,

- Komuro I. *Int Heart J.* 2020 Nov 28;61(6):1097-1106.
16. Novel Balloon Pulmonary Angioplasty Technique for Chronic Thromboembolic Pulmonary Hypertension. Minatsuki S, [Kiyosue A](#), Kodera S, Hirose K, Saito A, Maki H, Hatano M, Takimoto E, Ando J, Komuro I. *Int Heart J.* 2020;61(5):999-1004.
 17. Erratum: Diagnosing Heart Failure from Chest X-Ray Images Using Deep Learning. Matsumoto T, Kodera S, Shinohara H, Ieki H, Yamaguchi T, Higashikuni Y, [Kiyosue A](#), Ito K, Ando J, Takimoto E, Akazawa H, Morita H, Komuro I. *Int Heart J.* 2020;61(5):1088.
 18. Diagnosing Heart Failure from Chest X-Ray Images Using Deep Learning. Matsumoto T, Kodera S, Shinohara H, Ieki H, Yamaguchi T, Higashikuni Y, [Kiyosue A](#), Ito K, Ando J, Takimoto E, Akazawa H, Morita H, Komuro I. *Int Heart J.* 2020 Jul 30;61(4):781-786.
 19. Histone methylation and demethylation are implicated in the transient and sustained activation of the interleukin-1 β gene in murine macrophages. Imuta H, Fujita D, Oba S, [Kiyosue A](#), Nishimatsu H, Yudo K, Suzuki E. *Heart Vessels.* 2020 Dec;35(12):1746-1754.
 20. Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography. Masuda D, [Kiyosue A](#), Hirayama A, Shimauchi J, López JAG, Miyawaki K, Yamashita S. *J Atheroscler Thromb.* 2020 Nov 1;27(11):1183-1207.
 21. Balloon pulmonary angioplasty improves quality of life in Japanese patients with chronic thromboembolic pulmonary hypertension. Minatsuki S, Kodera S, [Kiyosue A](#), Saito A, Maki H, Hatano M, Takimoto E, Komuro I. *J Cardiol.* 2020 Aug;76(2):205-210.
 22. OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia. Kiriyaama H, Ishida J, Kadowaki H, Iwasa T, [Kiyosue A](#), Kodera S, Ando J, Akazawa H, Komuro I. *JACC CardioOncol.* 2019 Dec 17;1(2):318-321.
 23. Short-Term and Long-Term Efficacy of Drug-Coated Balloon for In-Stent Restenosis in Hemodialysis Patients with Coronary Artery Disease. Kiriyaama H, Kodera S, Minatsuki S, Kaneko H, Kikuchi H, [Kiyosue A](#), Toko H, Daimon M, Ando J, Morita H, Komuro I. *Int Heart J.* 2019 Sep 27;60(5):1070-1076.
 24. Effectiveness of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension despite having lesion types suitable for surgical treatment. Minatsuki S, [Kiyosue A](#), Kodera S, Hara T, Saito A, Maki H, Hatano M, Takimoto E, Ando M, Komuro I. *J Cardiol.* 2020 Feb;75(2):182-188.
 25. Overview of the 83rd Annual Scientific Meeting of the Japanese Circulation Society - Renaissance of Cardiology for the Creation of Future Medicine. Akazawa H, Toko

- H, Harada M, Ueda K, Kodera S, [Kiyosue A](#), Fujiu K, Hatano M, Daimon M, Ando J, Takimoto E, Morita H, Komuro I. *Circ J*. 2019 Aug 23;83(9):1829-1835.
26. Left Main Coronary Artery Obstruction by Huge Noncoronary Cusp Calcification After Transcatheter Aortic Valve Replacement. Kiriyama H, Kaneko H, Itoh H, Uehara M, Kodera S, [Kiyosue A](#), Yamauchi H, Daimon M, Ando J, Morita H, Ono M, Komuro I. *JACC Cardiovasc Interv*. 2019 Jul 8;12(13):1285-1287.
27. Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan. Kodera S, Morita H, [Kiyosue A](#), Ando J, Komuro I. *Circ J*. 2019 Jun 25;83(7):1498-1505.
28. Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial. Nomura A, Tanigawa T, Muto T, Oga T, Fukushima Y, [Kiyosue A](#), Miyazaki M, Hida E, Satake K. *J Med Internet Res*. 2019 Apr 26;21(4):e13520.
29. Long-Term Treatment With Evolocumab Among Japanese Patients - Final Report of the OSLER Open-Label Extension Studies. Hirayama A, Yamashita S, Ruzza A, Inomata H, Cyrille M, Lu C, Hamer AW, Yoshida M, [Kiyosue A](#), Teramoto T. *Circ J*. 2019 Apr 25;83(5):971-977.
30. Architecture of the Japan Ischemic Heart Disease Multimodal Prospective Data Acquisition for Precision Treatment (J-IMPACT) System. Matoba T, Kohro T, Fujita H, Nakayama M, [Kiyosue A](#), Miyamoto Y, Nishimura K, Hashimoto H, Antoku Y, Nakashima N, Ohe K, Ogawa H, Tsutsui H, Nagai R. *Int Heart J*. 2019 Mar 20;60(2):264-270.
31. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. Teramoto T, [Kiyosue A](#), Ishigaki Y, Harada-Shiba M, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. *J Cardiol*. 2019 Mar;73(3):218-227.
32. Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty. Minatsuki S, Hatano M, [Kiyosue A](#), Saito A, Maki H, Takimoto E, Komuro I. *Int Heart J*. 2018 Sep 26;59(5):1186-1188.
33. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Kodera S, Morita H, [Kiyosue A](#), Ando J, Takura T, Komuro I. *Circ J*. 2018 Sep 25;82(10):2602-2608.
34. Effectiveness of Nitroglycerin in Managing Subacute Lung Bleeding Induced by Balloon Pulmonary Angioplasty. Minatsuki S, [Kiyosue A](#), Saito A, Maki H, Hatano M, Komuro I. *Int Heart J*. 2018 Jul 31;59(4):899-901.
35. Coronary Artery Perforation During Percutaneous Coronary Intervention in a

- Patient with a Prior Modified Bentall Procedure. Tsuji M, Kodera S, Oshima T, Uehara M, [Kiyosue A](#), Ando J, Watanabe M, Yamauchi H, Ono M, Komuro I. *Int Heart J*. 2018 Jul 31;59(4):848-853.
36. Endogenous Interleukin-1 β Is Implicated in Intraplaque Hemorrhage in Apolipoprotein E Gene Null Mice. Suzuki E, Imuta H, Fujita D, Takahashi M, Oba S, [Kiyosue A](#), Nishimatsu H. *Circ J*. 2018 Mar 23;82(4):1130-1138.
 37. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Kodera S, Morita H, [Kiyosue A](#), Ando J, Komuro I. *Circ J*. 2018 Mar 23;82(4):1076-1082.
 38. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, [Kiyosue A](#). *Diabetes Obes Metab*. 2018 May;20(5):1202-1212.
 39. Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. Kodera S, [Kiyosue A](#), Ando J, Komuro I. *J Cardiol*. 2018 Mar;71(3):223-229.
 40. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. Kodera S, [Kiyosue A](#), Ando J, Akazawa H, Morita H, Watanabe M, Komuro I. *Int Heart J*. 2017 Dec 12;58(6):847-852.
 41. Usefulness of central venous saturation as a predictor of thiamine deficiency in critically ill patients: a case report. Numata G, Kodera S, Kiriyama H, Nakayama A, Amiya E, [Kiyosue A](#), Hatano M, Takimoto E, Watanabe M, Komuro I. *J Intensive Care*. 2017 Nov 6;5:61.
 42. Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. [Kiyosue A](#), Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. *J Diabetes Investig*. 2018 Jul;9(4):831-839.
 43. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Teramoto T, [Kiyosue A](#), Iimura T, Takita Y, Riesmeyer JS, Murakami M. *Circ J*. 2017 Dec 25;82(1):183-191.
 44. Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary

- Hypercholesterolemia. Teramoto T, [Kiyosue A](#), Iimura T, Takita Y, Riesmeyer JS, Murakami M. *Circ J*. 2017 Oct 25;81(11):1686-1692.
45. Effectiveness of Nitroglycerin in Managing Subacute Lung Bleeding Induced by Balloon Pulmonary Angioplasty. Minatsuki S, [Kiyosue A](#), Saito A, Maki H, Hatano M, Komuro I. *Int Heart J*. 2018 May 23.
 46. Coronary Artery Perforation During Percutaneous Coronary Intervention in a Patient with a Prior Modified Bentall Procedure. Tsuji M, Kodera S, Oshima T, Uehara M, [Kiyosue A](#), Ando J, Watanabe M, Yamauchi H, Ono M, Komuro I. *Int Heart J*. 2018 May 23.
 47. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, [Kiyosue A](#). *Diabetes Obes Metab*. 2018 May;20(5):1202-1212.
 48. Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan. Kodera S, [Kiyosue A](#), Ando J, Komuro I. *J Cardiol*. 2018 Mar;71(3):223-229.
 49. Endogenous Interleukin-1 β Is Implicated in Intraplaque Hemorrhage in Apolipoprotein E Gene Null Mice. Suzuki E, Imuta H, Fujita D, Takahashi M, Oba S, [Kiyosue A](#), Nishimatsu H. *Circ J*. 2018 Feb 22.
 50. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Kodera S, Morita H, [Kiyosue A](#), Ando J, Komuro I. *Circ J*. 2018 Jan 23.
 51. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Kaku K, Yamada Y, Watada H, Abiko A, Nishida T, Zacho J, [Kiyosue A](#). *Diabetes Obes Metab*. 2018 Jan 11.
 52. Nonfasting TG/HDL-C ratio seems a good predictor of MACE in CAD patients with statin therapy. Could it be a treatment target? [Kiyosue A](#). *J Cardiol*. 2018 Jan;71(1):8-9.
 53. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Teramoto T, [Kiyosue A](#), Iimura T, Takita Y, Riesmeyer JS, Murakami M. *Circ J*. 2017 Dec 25;82(1):183-191.
 54. Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. Kodera S, [Kiyosue A](#), Ando J, Akazawa H, Morita H, Watanabe M, Komuro I. *Int Heart J*.

2017 Dec 12;58(6):847-852.

55. Usefulness of central venous saturation as a predictor of thiamine deficiency in critically ill patients: a case report. Numata G, Kodera S, Kiriya H, Nakayama A, Amiya E, **Kiyosue A**, Hatano M, Takimoto E, Watanabe M, Komuro I. *J Intensive Care*. 2017 Nov 6;5:61.
56. Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia. Teramoto T, **Kiyosue A**, Iimura T, Takita Y, Riesmeyer JS, Murakami M. *Circ J*. 2017 Oct 25;81(11):1686-1692.
57. Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. **Kiyosue A**, Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. *J Diabetes Investig*. 2017 Oct 6.
58. One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies. Hirayama A, Yamashita S, Inomata H, Kassahun H, Cyrille M, Ruzza A, Yoshida M, **Kiyosue A**, Ma Y, Teramoto T. *Circ J*. 2017 Jun 23;81(7):1029-1035.
59. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Teramoto T, Kondo A, **Kiyosue A**, Harada-Shiba M, Ishigaki Y, Tobita K, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. *Lipids Health Dis*. 2017 Jun 17;16(1):121.
60. Identification of the State of Maximal Hyperemia in the Assessment of Coronary Fractional Flow Reserve Using Non-Invasive Electrical Velocimetry. Murasawa T, Takahashi M, Myojo M, **Kiyosue A**, Oguri A, Ando J, Komuro I. *Int Heart J*. 2017 May 31;58(3):365-370.
61. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. Katagiri M, Takahashi M, Doi K, Myojo M, **Kiyosue A**, Ando J, Hirata Y, Komuro I. *Heart Vessels*. 2016 Oct;31(10):1595-602.
62. Plasma neutrophil gelatinase-associated lipocalin predicts major adverse cardiovascular events after cardiac care unit discharge. Ito M, Doi K, Takahashi M, Koyama K, Myojo M, Hosoya Y, **Kiyosue A**, Ando J, Noiri E, Yahagi N, Hirata Y, Komuro I. *J Cardiol*. 2016 Feb;67(2):184-91.
63. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label,

- parallel-group trial. Kaku K, [Kiyosue A](#), Ono Y, Shiraiwa T, Kaneko S, Nishijima K, Bosch-Traberg H, Seino Y. *J Diabetes Investig.* 2016 Jan;7(1):76-84. Erratum in: *J Diabetes Investig.* 2016 Mar;7(2):279.
64. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. [Kiyosue A](#), Honarpour N, Kurtz C, Xue A, Wasserman SM, Hirayama A. *Am J Cardiol.* 2016 Jan 1;117(1):40-7.
65. Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease. Takahashi M, Myojo M, Watanabe A, [Kiyosue A](#), Kimura K, Ando J, Hirata Y, Komuro I. *Heart Vessels.* 2015 Sep;30(5):587-94.
66. Involvement of P2Y12 receptor in vascular smooth muscle inflammatory changes via MCP-1 upregulation and monocyte adhesion. Satonaka H, Nagata D, Takahashi M, [Kiyosue A](#), Myojo M, Fujita D, Ishimitsu T, Nagano T, Nagai R, Hirata Y. *Am J Physiol Heart Circ Physiol.* 2015 Apr 15;308(8):H853-61.
67. Midterm follow-up after retrievable inferior vena cava filter placement in venous thromboembolism patients with or without malignancy. Myojo M, Takahashi M, Tanaka T, Higashikuni Y, [Kiyosue A](#), Ando J, Fujita H, Komuro I, Hirata Y. *Clin Cardiol.* 2015 Apr;38(4):216-21.
68. Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation. Takahashi M, Miyazaki S, Myojo M, Sawaki D, Iwata H, [Kiyosue A](#), Higashikuni Y, Tanaka T, Fujita D, Ando J, Fujita H, Hirata Y, Komuro I. *PLoS One.* 2015 Mar 16;10(3):e0121079.
69. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Kaku K, Maegawa H, Tanizawa Y, [Kiyosue A](#), Ide Y, Tokudome T, Hoshino Y, Yang J, Langkilde AM. *Diabetes Ther.* 2014 Dec;5(2):415-33.
70. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Kaku K, [Kiyosue A](#), Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM. *Diabetes Obes Metab.* 2014
71. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. Myojo M, Nagata D, Fujita D, [Kiyosue A](#), Takahashi M, Satonaka H, Morishita Y, Akimoto T, Nagai R, Komuro I, Hirata Y. *PLoS One.* 2014 May 14;9(5):e96948.
72. Hydrogen peroxide regulates osteopontin expression through activation of transcriptional and translational pathways. Lyle AN, Remus EW, Fan AE, Lassègue B, Walter GA, [Kiyosue A](#), Griendling KK, Taylor WR. *J Biol Chem.* 2014 Jan 3;289(1):275-85.
73. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in

- Japanese patients with type 2 diabetes mellitus. **Kiyosue A**, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E. *Diabetes Obes Metab*. 2013 Oct;15(10):923-30.
74. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Kaku K, Inoue S, Matsuoka O, **Kiyosue A**, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. *Diabetes Obes Metab*. 2013 May;15(5):432-40.
75. Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial. Fukushima Y, Suzuki H, Matsuzaki J, **Kiyosue A**, Hibi T. *J Neurogastroenterol Motil*. 2012 Jul;18(3):317-23.
76. Prognostic implication of macrocytosis on adverse outcomes after coronary intervention. Myojo M, Iwata H, Kohro T, Sato H, **Kiyosue A**, Ando J, Sawaki D, Takahashi M, Fujita H, Hirata Y, Nagai R. *Atherosclerosis*. 2012 Mar;221(1):148-53.
77. Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. **Kiyosue A**, Nagata D, Myojo M, Sato T, Takahashi M, Satonaka H, Nagai R, Hirata Y. *Hypertens Res*. 2011 Dec;34(12):1283-7.
78. Prevalence of vitreous hemorrhage following coronary revascularization in patients with diabetic retinopathy. Kawashima D, Ohno T, Kinoshita O, Motomura N, **Kiyosue A**, Fujita H, Ando J, Ohtomo K, Shigeeda T, Kato S, Kadowaki T, Nagai R, Takamoto S, Ono M. *Circ J*. 2011;75(2):329-35.
79. Successful blood sampling through azygos continuation with interrupted inferior vena cava. A case report and review of the literature. Saito T, Watanabe M, Kojima T, Matsumura T, Fujita H, **Kiyosue A**, Takahashi M, Takeda N, Maemura K, Yamashita H, Hirata Y, Komatsu S, Ohtomo K, Nagai R.
80. Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. **Kiyosue A**, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M, Nagata D, Kohro T, Imai Y, Nagai R. *Circ J*. 2010 Nov;74(11):2441-7.
81. Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients. **Kiyosue A**, Hirata Y, Ando J, Fujita H, Morita T, Takahashi M, Nagata D, Kohro T, Imai Y, Nagai R. *Circ J*. 2010 Apr;74(4):786-91.
82. A new constitutively active mutant of AMP-activated protein kinase inhibits anoxia-induced apoptosis of vascular endothelial cell. Nagata D, **Kiyosue A**, Takahashi M, Satonaka H, Tanaka K, Sata M, Nagano T, Nagai R, Hirata Y. *Hypertens Res*. 2009 Feb;32(2):133-9.

83. Progression of renal dysfunction in patients with cardiovascular disease. Hirata Y, Kiyosue A, Takahashi M, Satonaka H, Nagata D, Sata M, Suzuki E, Nagai R. *Curr Cardiol Rev.* 2008 Aug;4(3):198-202.
84. New base pairing motifs. The synthesis and thermal stability of oligodeoxynucleotides containing imidazopyridopyrimidine nucleosides with the ability to form four hydrogen bonds. Minakawa N, Kojima N, Hikishima S, Sasaki T, Kiyosue A, Atsumi N, Ueno Y, Matsuda A. *J Am Chem Soc.* 2003 Aug 20;125(33):9970-82.